Completed enrollment of the safety portion of our Ph3 LIQ861 (INSPIRE) clinical trial Two-week safety Ph3 LIQ861 data readout anticipated in the first quarter of 2019 Dr. Stephen Bloch appointed as Chairman of the Board Management to host webcast and conference call today at 8 a.m.

RESEARCH TRIANGLE PARK, N.C. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT ® technology to transform the

RESEARCH TRIANGLE PARK, N.C. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the

RESEARCH TRIANGLE PARK, N.C. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the

RESEARCH TRIANGLE PARK, N.C. --(BUSINESS WIRE)--Jul. 30, 2018-- Liquidia Technologies, Inc. (the “Company”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of

RESEARCH TRIANGLE PARK, N.C. --(BUSINESS WIRE)--Jul. 25, 2018-- Liquidia Technologies, Inc. (the “Company”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT ® technology to transform the lives of

Liquidia Technologies, Inc. , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced that it has filed a registration statement on Form S-1

Liquidia Technologies, Inc.  (“Liquidia”), a late-stage clinical biopharmaceutical company focused on improving the performance of medicine by precisely engineering drug particles, today announced the appointment of Jeri Thomas as Senior Vice President, Commercial. Ms.